Advances in Surgical Treatment of Early-Stage Non-small Cell Lung Cancer
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Therapy".
Deadline for manuscript submissions: closed (30 December 2023) | Viewed by 3091
Special Issue Editor
Special Issue Information
Dear Colleagues,
Non-small cell lung cancer (NSCLC) is the most common form of lung cancer. It is typically treated with a combination of surgery, chemotherapy, and radiation therapy. In recent years, immune checkpoint inhibitor therapy has emerged as an effective treatment of NSCLC. Surgical techniques used to treat NSCLC include lobectomy, segmentectomy, and wedge resection. These techniques involve the removal of part or all of the affected lung tissue. Additionally, newer techniques such as robotic surgery and minimally invasive surgery are being used to improve outcomes and reduce recovery time.
This Special Issue focuses on the most recent advancements in the surgical treatment of early-stage non-small cell lung cancer. It will include reviews of the latest clinical trials and research, as well as perspectives from leading experts in the field. We hope that it can provide a platform for further research and development in this field.
Dr. Robert E. Merritt
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- non-small cell lung cancer
- surgery
- therapy
- chemotherapy
- immune checkpoint inhibitor therapy
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.